GI CANCERS

Dr. Filippo Pietrantonio explores the manageable safety profile of amivantamab combined with chemotherapy for metastatic colorectal cancer patients.

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating patients with advanced rectal cancer with high Immunoscores.

Dr. Filippo Pietrantonio explores how amivantamab may transform surgical options for patients with advanced colorectal cancer, enhancing treatment outcomes.

Atebimetinib shows promising 1-year survival rates in pancreatic cancer patients, potentially transforming treatment options with manageable safety profiles.

New data from the OrigAMI-1 study highlights promising efficacy and safety of amivantamab with chemotherapy for metastatic colorectal cancer patients.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

New research reveals comparable outcomes for STZ/5-FU and everolimus in treating advanced pancreatic neuroendocrine tumors, guiding personalized treatment strategies.

Filippo Pietrantonio discusses overcoming resistance in metastatic colorectal cancer with innovative trials for amivantamab, enhancing treatment efficacy.

FDA approves Guardant360 CDx for identifying BRAF V600E-mutant colorectal cancer patients, enhancing precision therapy with encorafenib and cetuximab.

Experts discuss optimizing NALIRIFOX treatment for metastatic pancreatic cancer, highlighting flexible dosing and early adverse event recognition for better patient outcomes.

Zenocutuzumab shows promising efficacy in advanced NRG1+ pancreatic and cholangiocarcinoma, offering hope for patients after disease progression.

New trial data reveals promising results for pelareorep and atezolizumab in treating advanced anal cancer, significantly improving response rates and duration.

New research highlights amivantamab's potential in enhancing treatment outcomes for RAS/BRAF wild-type metastatic colorectal cancer, addressing resistance to standard therapies.

Investigational therapy [212Pb]VMT-α-NET shows promising antitumor activity in advanced neuroendocrine tumors, with ongoing trials and favorable safety profile.

New data reveals that elraglusib combined with chemotherapy significantly improves survival rates in metastatic pancreatic cancer patients, offering hope for better outcomes.

A novel oral fascin inhibitor, NP-G2-044, shows promise in treating pancreatic cancer, earning FDA orphan drug designation for innovative therapies.

New trial data highlight zanidatamab's potential to enhance survival in HER2-positive gastroesophageal adenocarcinoma, challenging existing treatment standards.

A recent study reveals that combining mFOLFOX6 and bevacizumab with atezolizumab significantly enhances progression-free survival (PFS) in patients with metastatic colorectal cancer.

New research highlights the benefits of physical activity, particularly walking, in reducing cancer-related fatigue and enhancing quality of life for colorectal cancer survivors.

A new integrated treatment regimen significantly enhances PFS vs standard chemotherapy in metastatic pancreatic cancer.

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid limited options.

A groundbreaking blood test for colorectal cancer shows enhanced sensitivity, promising earlier detection and improved patient outcomes in upcoming studies.

Jason S. Starr, DO, discusses his approach to dose reduction of cabozantinib in patients with neuroendocrine tumors.

CPI-008 receives orphan drug designation, enhancing surgical imaging for pancreatic cancer and promising improved outcomes in challenging surgeries.

Breakthroughs in GI cancer treatment in 2025 showcase innovative therapies, including daraxonrasib for pancreatic cancer and aspirin's role in colorectal cancer recurrence.